WILGO RESEARCH INDEX

KPV

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). Its research literature centers on anti-inflammatory signaling, intestinal transport, and experimental colitis models, with evidence primarily from cells and animals rather than human therapeutic trials.

Lys-Pro-Valα-MSH-derivedInflammation researchPepT1 transportColitis models

VIEW RESEARCH ↓

EVIDENCE MAP

What kind of evidence exists?

KPV has a coherent mechanistic/preclinical literature, but direct human clinical evidence is much thinner.

Cellular evidenceResearch examines inflammatory signaling and peptide transport in intestinal-cell systems.

Animal evidenceMurine colitis models report reductions in inflammatory measures after KPV exposure.

Transport mechanismPepT1 has been implicated in intestinal uptake and targeting of KPV.

Human translationPreclinical anti-inflammatory activity does not establish treatment effectiveness in inflammatory bowel disease or other conditions.

KPV is a preclinical research story, not a clinical one.

The selected literature is mechanistically interesting and internally consistent, but it should not be written as though KPV were an established human anti-inflammatory therapy.

PUBLISHED LITERATURE

Selected studies.

Selected sources are grouped by study type so model limitations remain visible.

PRECLINICAL · COLITIS

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

PMID 18092346

KPV showed anti-inflammatory effects in two mouse colitis models, supporting investigation of melanocortin-derived tripeptides in intestinal inflammation.

PUBMED →

MECHANISTIC · PEPT1

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

PMID 18061177

The work linked KPV uptake through the PepT1 transporter with reduced inflammatory signaling and lower disease measures in experimental colitis systems.

PUBMED →

PRECLINICAL · TARGETED DELIVERY

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

PMID 28143741

A nanoparticle-delivery strategy was tested to target KPV to inflamed colon tissue in experimental colitis, illustrating formulation research rather than human clinical efficacy.

PUBMED →

REVIEW · MELANOCORTIN

alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs

PMID 17934097

The review attributes many anti-inflammatory activities of α-MSH to its C-terminal KPV sequence and surveys inflammatory disease models across multiple organ systems.

PUBMED →

REVIEW · TRIPEPTIDES

Alpha-melanocyte-stimulating hormone and related tripeptides

PMID 18612139

This review discusses KPV as a non-pigmentary α-MSH-derived tripeptide retaining anti-inflammatory activity in preclinical models.

PUBMED →

REFERENCES

Primary sources.

Direct PubMed links are used wherever possible.

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel diseasePMID 18092346 · PubMed →

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationPMID 18061177 · PubMed →

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid Functionalized Nanoparticles Efficiently Alleviates Ulcerative ColitisPMID 28143741 · PubMed →

alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugsPMID 17934097 · PubMed →

Alpha-melanocyte-stimulating hormone and related tripeptidesPMID 18612139 · PubMed →

Research-use notice: This resource summarizes published scientific literature for informational and research-reference purposes. It does not provide medical advice, dosing, reconstitution, injection, therapeutic, diagnostic, or other human-use instructions. WILGO products are intended for laboratory research use only and are not presented for human or animal consumption, diagnosis, treatment, prevention, weight management, cosmetic use, or self-administration.